‍

Understanding the Contraindications: Who Should Not Consider IV MSCs Treatment?

Intravenous Mesenchymal Stem Cell (IV MSC) therapy is a promising field of regenerative medicine that has shown potential in treating a variety of health conditions. However, like any medical treatment, it is not suitable for everyone. Understanding the contraindications of IV MSC therapy is crucial for patient safety and treatment efficacy.

Mesenchymal Stem Cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells), and adipocytes (fat cells). IV MSC therapy involves the infusion of these cells into a patient's bloodstream, where they can travel to areas of damage or inflammation and aid in tissue repair and regeneration.

Despite the potential benefits of IV MSC therapy, certain individuals should exercise caution  due to specific contraindications.

1. Individuals with Active Infections or Immune Disorders

Patients with active infections, particularly those that are systemic, should not undergo IV MSC therapy. MSCs have immunomodulatory properties, meaning they can alter the immune response. While this can be beneficial in conditions like autoimmune diseases, it can potentially exacerbate an active infection by suppressing the body's immune response. This can be a dual edged sword, so it's crucial that you speak with an experienced physician with expertise in this area.

Similarly, individuals with immune disorders should approach IV MSC therapy with caution. The immunomodulatory effects of MSCs can potentially disrupt the delicate balance of the immune system in these individuals, leading to unforeseen complications.

2. Individuals with Malignancies

Patients with active malignancies or a history of cancer should avoid IV MSC therapy. While research is ongoing, some studies suggest that MSCs can enhance tumor growth and metastasis. This is because MSCs can create a supportive environment for cancer cells, helping them to grow and spread. Therefore, until more is known about the interactions between MSCs and cancer cells, it is safer for these individuals to avoid this therapy.

This is an important reason to make sure you have ruled out active cancer before considering IV Stem Cell Therapy. Ask your doctor about having a blood test for "cancer tumor markers." Although not very specific, tests for tumor markers can alert your doctor about otherwise silent cancer.

3. Individuals with Certain Genetic Disorders

Certain genetic disorders, particularly those affecting the bone marrow or immune system, may be contraindications for IV MSC therapy. These conditions can affect the quality and function of MSCs, potentially reducing the efficacy of the treatment or leading to adverse effects.

4. Individuals with Severe Cardiovascular Disorders

Patients with severe cardiovascular disorders, particularly those with unstable angina or recent myocardial infarction, should avoid IV MSC therapy. The infusion of MSCs could potentially lead to clot formation, which could exacerbate these conditions.

5. Pregnant or Breastfeeding Women

As a general rule, pregnant or breastfeeding women should avoid any treatments that have not been thoroughly tested for safety in this population. As of now, there is insufficient data on the effects of IV MSC therapy on pregnancy and lactation.

In conclusion, while IV MSC therapy holds promise for the treatment of a variety of conditions, it is not suitable for everyone. Individuals with active infections, immune disorders, malignancies, certain genetic disorders, severe cardiovascular disorders, and pregnant or breastfeeding women should avoid this therapy. As always, it is crucial to discuss any potential treatments with a healthcare provider to understand the benefits and risks fully.

The field of regenerative medicine is rapidly evolving, and as more research is conducted, our understanding of the contraindications and potential applications of IV MSC therapy will continue to grow. It is an exciting time in medicine, and the future holds much promise for the potential of stem cell therapies.

‍

Below are a list of references specifically about contraindications to stem cell therapy.

‍

1. Sequential Use of High-Volume Plasma Exchange and Continuous Renal Replacement Therapy in Hepatitis B Virus-Related Acute Liver Failure: A Case Report by S. Bragança, Mário Ferraz, N. Germano. This paper discusses a case of acute liver failure where the patient was not a candidate for liver transplantation due to a simultaneously diagnosed malignant neoplasm. However, it doesn't directly address contraindications for IV MSCs therapy.
2. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update by G. Masters, S. Temin, C. Azzoli, G. Giaccone, Sherman Baker, J. Brahmer, P. Ellis, A. Gajra, Nancy Rackear, J. Schiller, Thomas J. Smith, John R. Strawn, D. Trent, David H. Johnson. This paper provides recommendations for systemic therapy for stage IV non-small-cell lung cancer, but it doesn't directly address contraindications for IV MSCs therapy.
3. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update by N. Hanna, B. Schneider, S. Temin, Sherman Baker, J. Brahmer, P. Ellis, L. Gaspar, Rami Y. Haddad, P. Hesketh, D. Jain, I. Jaiyesimi, David H Johnson, N. Leighl, Tanyanika Phillips, Gregory Riely, A. Robinson, R. Rosell, J. Schiller, Navneet Singh, D. Spigel, Janis O Stabler, Joan Tashbar, G. Masters. This paper provides recommendations for therapy for stage IV non-small-cell lung cancer without driver alterations, but it doesn't directly address contraindications for IV MSCs therapy.
4. Bone marrow-derived mesenchymal stem cells combined with gonadotropin therapy restore postnatal oogenesis of chemo-ablated ovaries in rats via enhancing very small embryonic-like stem cells by Nesrine Ebrahim, H.A. Al Saihati, A. Shaman, A. Dessouky, A. Farid, Noha I Hussien, O. Mostafa, Y. Seleem, D. Sabry, A. Saad, H. Emam, A. Hassouna, O. Badr, B. Saffaf, N. Forsyth, Rabab F. Salim. This paper discusses the use of bone marrow-derived mesenchymal stem cells combined with gonadotropin therapy to restore postnatal oogenesis in chemo-ablated ovaries in rats.

‍